Critically ill COVID-19 patients who received a single dose of a drug that calms an overreacting immune system were 45% less likely to die overall, and more likely to be out of the hospital or off a ventilator one month after treatment, compared with those who didn’t receive the drug, a new study finds. The lower risk of death happened despite the fact that the patients were also twice as likely to develop another infection.
- Tube-dwelling anemone toxins have pharmacological potential, mapping study shows
- Autoantibody order, timing predict genetically at-risk children most likely to get T1D
- Landscape to atomic scales: Researchers apply new approach to pyrite oxidation
- World’s first agreed guidance for people with diabetes to exercise safely
- Models show how COVID-19 cuts a neighborhood path